Acrivon (ACRV) CEO Peter Blume-Jensen Sells 14,036 Shares

What Happened Peter Blume-Jensen, President, CEO and a director of Acrivon Therapeutics (ACRV), sold 14,036 shares on 2026-08-25 in a sale totaling about $30,969. The filing lists the transaction as a sale (S) and notes the shares were sold to satisfy mandatory tax withholding upon vesting of restricted stock units (RSUs), so this was a routine tax-withholding disposition rather than a discretionary market-sale signal.

Key Details

• Transaction date: 2026-08-25; Form 4 filed: 2026-08-27 (timely filing).
• Shares sold: 14,036; reported weighted-average price: $2.21; total proceeds reported: $30,969.
• Sale executed in multiple trades at prices ranging from $2.17 to $2.25; reporting person offered to provide per-trade breakdown on request (footnote F2).
• Reason for sale: automatic share sale to satisfy mandatory tax withholding upon RSU vesting (footnote F1).
• Shares owned after transaction: Not specified in the provided filing data.
• Spousal disclaimers included in filing (footnotes F3 and F4) noting certain securities are held by the insider or the insider’s spouse and each disclaims beneficial ownership of the other’s holdings except to the extent of pecuniary interest.

Context This was a tax-withholding sale tied to RSU vesting (common and generally not interpreted as a bullish or bearish trading signal). The filing appears timely (reported within two business days). For investors, purchases by insiders typically carry more weight than routine withholding sales; this transaction primarily documents compensation-related share disposition.